Supporting advanced therapies with the largest global network of qualified cryogenic charging stations 

Our global LN2 and Via Capsule charging capabilities provide convenient and reliable solutions for your shipments. We can also tailor a custom solution to fit your unique needs and requirements, no matter where you are shipping from or to. Regions not covered: Cuba, Iran, Syria, Eastern Ukraine, Crimea, North Korea

To support the growth of the advanced therapy medical product (ATMP) industry and enable more patients than ever before to be treated with these life-changing therapies, World Courier utilizes its global network of liquid nitrogen (LN2) charging centers and stations.

This network is built on World Courier’s existing infrastructure, leveraging our owned LN2 charging centers (office or depot locations), vetted vendors’ charging stations, and capsule charging centers. This means that ATMP developers can immediately benefit from an established and qualified operation with access to cryogenic shipping solutions close to patient and manufacturing locations.

Our network capabilities enable access to a range of cryogenic shippers with shorter lead times and reduced positioning costs.

One of the challenges within the ATMP industry is the delivery of critical shipments, such as aphaeresis donations and final therapies. The short shelf life of fresh shipments and the resulting logistics complexity may encourage therapy developers to qualify cryopreserved transport. To enable this solution, dry shippers need to be charged with LN2 by fully trained staff for both the LN2 discharge and the processes for filling the dewar(s) This is a specialized process, in which dry shippers must be:

• Inspected and cleaned prior to use
• Fully charged, with supporting documentation
• Positioned when and where required in readiness for these highly critical therapies

Only after those stringent steps have been taken can the critical shipment take place. These preparations take time, especially when a charging center or station may be located in another country from the clinic or manufacturing site.

Although the field is still in its relative infancy with 27 treatments approved by the U.S. Food and Drug Administration (FDA) and 22 approved by the European Union’s (EU) European Medicines Agency (EMA), the development pipeline is growing fast. These are inclusive of cell-based immunotherapy products, gene therapy products, cell therapy products and tissue-engineered products. There were over a 1,000 industry clinical trials in 2022, including several in phase III¹.

Data shows there are over 1,350 therapy developers globally. To support this growth, World Courier has a fleet of cryogenic dry shippers, as well as the ability to charge and ship customers’ units throughout its global network of strategically located owned charging stations and vetted vendors’ charging stations to offer near-total global coverage.

The strategic intention is to leverage a network of owned and qualified vendor charging stations as well as unit suppliers to develop unmatched worldwide coverage as globalization of cryogenic services continues. By utilizing its global network, World Courier helps advanced therapy companies build robust logistics platforms that support the clinical development and commercialization of therapies to meet patient treatment needs.

¹ ARM Quarterly Reports